Neurokine Therapeutics
NY - New YorkBiotechnology
Focus: Neurokine Therapeutics is a neurology-focused biotech company developing orally bioavailable p38α MAPK inhibitors for neurodegenerative diseases. The company is early-stage with a single Phase 2 program and minimal public footprint.
Profile data last refreshed 9h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Neurokine Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Neurokine Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Neurokine Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
0/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
MW150
Alzheimer DiseaseOpen Jobs (0)
No open positions listed yet.
Help build intelligence for Neurokine Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.